Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$7.54 +4.3%	$6.85	$4.09 ▼ $15.92	$154.55M	0.84	280,230 shs	213,585 shs
IMRX Immuneering	$4.13 -4.0%	$2.58	$1.00 ▼ $4.60	$154.74M	0.38	2.58 million shs	317,161 shs
LVTX LAVA Therapeutics	$1.42 +1.4%	$1.32	$0.85 ▼ $2.21	$36.83M	0.48	150,709 shs	23,804 shs
SPRO Spero Therapeutics	$2.37 -4.4%	$2.26	$0.51 ▼ $3.22	$138.66M	1.33	1.24 million shs	969,965 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	+4.29%	+14.94%	+4.29%	+47.84%	-52.34%
IMRX Immuneering	-3.95%	-6.56%	+49.10%	+225.20%	+252.99%
LVTX LAVA Therapeutics	+1.43%	+4.41%	+9.57%	+8.40%	-37.99%
SPRO Spero Therapeutics	-4.44%	-15.66%	-19.39%	+214.24%	+60.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	3.7706 of 5 stars	3.4	1.0	4.7	2.0	2.5	0.0
IMRX Immuneering	3.4291 of 5 stars	3.3	2.0	0.0	3.4	5.0	0.6
LVTX LAVA Therapeutics	2.0681 of 5 stars	3.0	5.0	0.0	2.7	0.0	0.0
SPRO Spero Therapeutics	3.948 of 5 stars	3.3	3.0	4.7	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	138.73% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.25	220.82% Upside
LVTX LAVA Therapeutics	2.00	Hold	$3.17	123.00% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	110.97% Upside

Current Analyst Ratings Breakdown

Latest LVTX, IMRX, ENTA, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$67.64M	2.38	N/A	N/A	$6.08 per share	1.24
IMRX Immuneering	$320K	464.50	N/A	N/A	$1.33 per share	3.11
LVTX LAVA Therapeutics	$11.98M	3.12	N/A	N/A	$1.06 per share	1.34
SPRO Spero Therapeutics	$47.98M	2.76	N/A	N/A	$0.85 per share	2.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-86.38%	-34.12%	8/19/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest LVTX, IMRX, ENTA, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	IMRX Immuneering	-$0.40	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
8/4/2025	Q2 2025	SPRO Spero Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	LVTX LAVA Therapeutics	-$0.37	-$0.13	+$0.24	-$0.13	N/A	N/A
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
IMRX Immuneering	N/A	7.48	7.48
LVTX LAVA Therapeutics	N/A	6.73	6.73
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
IMRX Immuneering	67.65%
LVTX LAVA Therapeutics	N/A
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
IMRX Immuneering	22.90%
LVTX LAVA Therapeutics	9.50%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

LVTX, IMRX, ENTA, and SPRO Headlines

Recent News About These Companies

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?

July 1, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street Zen

June 21, 2025 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?

June 19, 2025 | marketbeat.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 29, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Super Micro Computer Stock's Rally Backed by Strong Financials
By Gabriel Osorio-Mazilli | June 19, 2025
View Super Micro Computer Stock's Rally Backed by Strong Financials
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop

LVTX, IMRX, ENTA, and SPRO Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$7.54 +0.31 (+4.29%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.40 -0.14 (-1.84%)

As of 07/18/2025 04:31 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Immuneering NASDAQ:IMRX

$4.13 -0.17 (-3.95%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.02 (+0.51%)

As of 07/18/2025 07:55 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

LAVA Therapeutics NASDAQ:LVTX

$1.42 +0.02 (+1.43%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$1.42 0.00 (-0.35%)

As of 07/18/2025 04:04 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Spero Therapeutics NASDAQ:SPRO

$2.37 -0.11 (-4.44%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.34 -0.03 (-1.43%)

As of 07/18/2025 07:50 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time